{
  "id": "radionuclide-therapy",
  "title": "Radionuclide Therapy",
  "lang": "en",
  "source_lang": "en",
  "summary": "Radionuclide therapy uses radioactive substances delivered to selected tissues to treat cancer and certain nonmalignant disorders.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Radioisotope therapy",
    "Radiopharmaceutical therapy",
    "Molecular radiotherapy"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/radionuclide-therapy/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/radionuclide-therapy/",
      "json": "https://aiwiki.page/zh/radionuclide-therapy.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Radionuclide therapy is treatment with radioactive substances administered into the body to deliver ionizing radiation to selected tissues. A major branch of nuclear medicine, it is used for several forms of cancer and for some nonmalignant conditions, particularly an overactive thyroid. The therapeutic agent may be a simple radioactive ion, a molecule that binds to a cellular target, or radioactive particles placed within a particular anatomical compartment. Treatment can eliminate functioning tissue, control tumor growth, prolong survival, or relieve symptoms.\n\nUnlike external-beam radiation therapy, radionuclide therapy usually distributes its radiation source through biological processes rather than directing a beam from outside the body. Unlike sealed-source brachytherapy, most treatments use unsealed radioactive preparations. The resulting radiation distribution depends jointly on radioactive decay, the agent’s chemical properties, blood flow, target expression, and biological clearance.\n\nThe field includes established treatments such as iodine-131 for thyroid disease, receptor-directed therapy for neuroendocrine tumors, prostate-specific membrane antigen–directed treatment, bone-seeking agents, radioimmunotherapy, and liver-directed radioembolization. Its defining technical challenge is to deliver enough absorbed radiation to diseased tissue while limiting irradiation of healthy organs."
    },
    {
      "heading": "Physical and biological principles",
      "text": "A therapeutic radioisotope contains an unstable atomic nucleus that releases energy as it decays. The principal emissions used for treatment are beta particles, alpha particles, and, in selected applications, low-energy electrons including Auger electrons. Gamma rays and other photons accompanying decay may permit imaging, but they also contribute to radiation exposure outside the patient. The choice of radionuclide therefore affects both the biological action of treatment and the facilities required to administer it.\n\nBeta particles are energetic electrons or positrons emitted during nuclear decay, although therapeutic beta emitters generally release electrons. Their tissue ranges vary with energy and extend from fractions of a millimeter to several millimeters. Radiation from one labeled cell can consequently reach neighboring cells, producing a “cross-fire” effect. This can partly compensate for uneven uptake within a tumor. Iodine-131, lutetium-177, and yttrium-90 are important beta-emitting therapeutic radionuclides, with physical half-lives of approximately 8.0 days, 6.6 days, and 64 hours, respectively.\n\nAlpha particles consist of two protons and two neutrons. They deposit substantial energy over a short path, generally several tens of micrometers in tissue. Their high linear energy transfer produces densely clustered damage, including complex breaks in DNA, and can kill cells after relatively few nuclear traversals. Radium-223, with a half-life of approximately 11.4 days, is an established therapeutic alpha emitter. Actinium-225 and lead-212–based decay systems are being investigated in targeted treatments. For radionuclides with radioactive daughters, the behavior of the entire decay chain matters: daughter atoms may redistribute after the parent decays.\n\nAuger electrons have much shorter ranges, and their effectiveness depends strongly on whether decay occurs near critical cellular structures, especially nuclear DNA. This makes intracellular trafficking particularly important for Auger-based strategies. More generally, cell killing depends not only on total deposited energy but also on dose rate, radiation quality, oxygenation, repair capacity, and the microscopic distribution of radioactivity.\n\nRadiation delivery continues as long as the radionuclide remains in the body and has not decayed. Most treatments therefore expose tissue over hours or days rather than in brief external-beam sessions. Tumor shrinkage may develop over weeks or months. Biological response can also include vascular injury and changes in the tumor microenvironment, but their importance varies by agent and disease."
    },
    {
      "heading": "Targeting, imaging, and absorbed-dose calculation",
      "text": "A radiopharmaceutical combines a radionuclide with a chemical form suitable for administration. Some agents exploit normal physiology: iodide enters thyroid cells through the sodium–iodide symporter, while bone-seeking compounds accumulate where bone mineral is being actively deposited. Others use peptides, small-molecule ligands, or antibodies that recognize particular tumor-associated targets. The targeting component determines much of the agent’s pharmacokinetics, while the radionuclide determines its decay characteristics.\n\nFor radiometal-based agents, a chelating group commonly holds the radioactive metal and connects it to the targeting molecule. The complex must remain sufficiently stable in blood and tissue; otherwise, released radioactivity may accumulate in unintended organs. Molecular size, charge, protein binding, and receptor internalization influence tumor uptake and clearance. Small peptides often clear rapidly through the kidneys, whereas intact antibodies commonly remain in circulation longer and may expose the blood and marrow for extended periods.\n\nTheranostics links diagnostic imaging with treatment directed at the same biological target. For example, a gallium-68–labeled somatostatin receptor ligand can map receptor-positive disease before treatment with a lutetium-177–labeled ligand. Imaging with positron emission tomography or single-photon emission computed tomography can identify disease distribution and help assess whether a target is expressed. Diagnostic and therapeutic agents are not always chemically identical, however, so an imaging tracer does not perfectly predict therapeutic biodistribution.\n\nActivity and absorbed dose describe different quantities. Activity, measured in becquerels, is the number of nuclear decays per second; absorbed dose, measured in grays, is energy deposited per unit mass, with \\(1\\ \\mathrm{Gy}=1\\ \\mathrm{J\\,kg^{-1}}\\). An administered activity in gigabecquerels does not by itself specify the radiation dose received by a tumor or organ. In the Medical Internal Radiation Dose framework, a common expression is\n\n\\[D(r_T)=\\sum_{r_S}\\widetilde{A}(r_S)\\,S(r_T\\leftarrow r_S),\\]\n\nwhere \\(\\widetilde{A}(r_S)\\) is time-integrated activity in a source region and \\(S(r_T\\leftarrow r_S)\\) represents absorbed dose to a target region per unit time-integrated activity in that source.\n\nInternal dosimetry may use serial imaging, blood measurements, organ volumes, and computational models. Physical decay and biological elimination both determine residence time. Under a simple single-exponential model, the effective half-life satisfies \\(1/T_{\\mathrm{eff}}=1/T_{\\mathrm{phys}}+1/T_{\\mathrm{bio}}\\). Actual tissue kinetics can be more complex, and small lesions, heterogeneous uptake, image resolution, and calibration introduce important uncertainties."
    },
    {
      "heading": "Radioiodine treatment of thyroid disease",
      "text": "Radioiodine treatment exploits the thyroid’s physiological requirement for iodine to synthesize thyroid hormones. Thyroid follicular cells concentrate iodide, and functioning thyroid tissue can therefore receive a much higher radiation dose than most other tissues after administration of iodine-131. Its beta emission supplies most of the therapeutic irradiation; its gamma emission permits imaging and contributes to external exposure.\n\nIn hyperthyroidism, iodine-131 reduces the mass and function of overactive thyroid tissue. Established indications include Graves disease, toxic multinodular goiter, and autonomously functioning thyroid nodules. The biological basis differs among these disorders: Graves disease involves stimulation of the thyroid by receptor-directed autoantibodies, whereas autonomous nodules function relatively independently of normal hormonal control. Radioiodine does not act immediately, because functional decline follows radiation injury and tissue turnover.\n\nHypothyroidism is a common long-term outcome, especially after treatment of Graves disease, and is an expected consequence of some treatment strategies rather than necessarily an accidental complication. Radiation thyroiditis can cause transient local discomfort or release of stored hormone. Graves orbitopathy is a separate clinical consideration because thyroid treatment and changes in thyroid status can affect its course. Treatment selection therefore depends on more than biochemical evidence of excess hormone production.\n\nIn differentiated thyroid carcinoma, principally papillary and follicular cancers, iodine-131 may be used after surgery to ablate residual normal thyroid tissue, treat suspected microscopic disease, or treat known iodine-avid persistent or metastatic disease. These are distinct objectives, and not every patient with differentiated thyroid cancer receives radioiodine. Medullary thyroid carcinoma arises from parafollicular C cells and generally does not share the iodide-concentrating mechanism; anaplastic thyroid carcinoma also usually lacks clinically useful iodine uptake.\n\nRadioiodine uptake is influenced by thyroid-stimulating hormone, iodine availability, and preservation of thyroid-cell differentiation. Tumors that lose iodine-handling functions may become radioiodine-refractory even while continuing to grow. Follow-up can involve structural imaging, radioiodine imaging, and thyroglobulin measurements interpreted in their clinical context. Recognized adverse effects include salivary gland injury, dry mouth, altered taste, and, with greater cumulative exposure, marrow effects and an increased risk of certain second malignancies. Radioiodine is not administered during pregnancy, and breastfeeding is an important contraindication because iodine can concentrate in breast tissue and enter milk."
    },
    {
      "heading": "Peptide receptor radionuclide therapy for neuroendocrine tumors",
      "text": "Peptide receptor radionuclide therapy, commonly abbreviated PRRT, uses radiolabeled peptides to bind receptors expressed by a tumor. Its best-established application targets somatostatin receptors in well-differentiated neuroendocrine tumors. These neoplasms can arise in the gastrointestinal tract, pancreas, lungs, and other sites. Their behavior varies substantially with site, differentiation, proliferative activity, hormone secretion, and disease extent.\n\nSomatostatin is a regulatory peptide whose receptors are expressed by many well-differentiated neuroendocrine tumors. Synthetic analogues bind these receptors and can carry a radioactive payload. Lutetium-177 dotatate contains a somatostatin analogue linked through the DOTA chelator to lutetium-177. After receptor binding and internalization, retained radioactivity irradiates tumor cells and nearby tissue. Receptor imaging is used to establish whether disease has sufficient target expression for this approach.\n\nThe phase 3 NETTER-1 randomized controlled trial, reported in 2017, compared lutetium-177 dotatate plus standard-dose octreotide with high-dose octreotide in patients with progressive, somatostatin receptor–positive midgut neuroendocrine tumors. Estimated progression-free survival at 20 months was 65.2% in the lutetium group and 10.8% in the control group. Objective tumor responses also occurred more often with radionuclide treatment. These results supported its adoption, although the final overall-survival analysis did not show a statistically significant difference between groups.\n\nThe kidneys and bone marrow are important organs at risk. Radiolabeled peptides are filtered by the kidneys and can be reabsorbed in proximal tubular cells. Infusions containing lysine and arginine reduce renal retention by interfering with this reabsorption. Their administration can itself produce nausea and other acute effects. Previous cytotoxic treatment, extensive bone disease, impaired renal function, and limited marrow reserve can influence the toxicity profile.\n\nPRRT is usually delivered in a series of treatment cycles rather than as one large exposure. Assessment includes both imaging and clinical outcomes: stabilization of a slowly growing tumor may be meaningful even without major shrinkage, while control of hormone-related symptoms is relevant in functioning tumors. Uncommon but important delayed complications include myelodysplastic syndrome and acute myeloid leukemia. Re-treatment, use earlier in the disease course, and applications to other receptor systems are areas of clinical investigation rather than interchangeable extensions of the established regimen."
    },
    {
      "heading": "Prostate-directed and bone-seeking treatments",
      "text": "Radionuclide treatment of prostate cancer includes two biologically different approaches: targeting a molecule expressed by prostate cancer cells and targeting the bone environment around skeletal metastases. These approaches can overlap in the same disease but do not irradiate the same anatomical structures or require the same imaging evidence.\n\nProstate-specific membrane antigen, or PSMA, is a cell-surface protein frequently expressed at high levels in prostate cancer. Small-molecule PSMA ligands can carry lutetium-177 to PSMA-expressing lesions. Expression is not uniform across all tumors, and PSMA is also present in some normal tissues. Salivary glands, lacrimal glands, kidneys, and marrow are relevant to treatment distribution or toxicity. PSMA-targeted imaging assesses whether the visible disease expresses the target sufficiently and whether substantial target-negative disease is present.\n\nIn the phase 3 VISION trial, published in 2021, lutetium-177 PSMA-617 was added to protocol-permitted standard care in selected patients with previously treated, PSMA-positive metastatic castration-resistant prostate cancer. Median overall survival was 15.3 months with the radioligand combination and 11.3 months with standard care alone. Median imaging-based progression-free survival was 8.7 versus 3.4 months. These results apply to the population and treatment setting studied; they do not establish that every prostate cancer phenotype is susceptible to PSMA-directed irradiation. Later trials have examined use at other points in the treatment sequence.\n\nRadium-223 dichloride instead behaves as a calcium analogue and localizes to areas of active bone formation. Its short-range alpha emissions irradiate the bone metastatic microenvironment. The ALSYMPCA trial, reported in 2013, established a survival benefit in patients with castration-resistant prostate cancer and symptomatic bone metastases without known visceral metastases. Median overall survival was 14.9 months with radium-223 and 11.3 months with placebo, alongside best standard care in both groups. Radium-223 is not a treatment for soft-tissue metastases.\n\nOther bone-seeking agents include strontium-89 chloride and samarium-153 lexidronam. These have been used principally to palliate pain from osteoblastic skeletal metastases rather than to provide the survival evidence associated with radium-223. Because bone-targeted radioactivity can irradiate nearby marrow, cytopenias are important adverse effects. Fracture outcomes have also influenced the evaluation of radium-223 combinations, particularly after the ERA 223 trial found increased fractures when it was added to abiraterone and prednisone or prednisolone. The safety of a combination cannot be inferred from the properties of each component alone."
    },
    {
      "heading": "Radioimmunotherapy and other systemic applications",
      "text": "Radioimmunotherapy attaches a radionuclide to an antibody that recognizes an antigen on target cells. Antibodies provide high binding specificity, but their relatively large size and slow clearance create a different radiation-delivery pattern from that of small peptides. Circulating radioactivity may persist for days, and delivery into solid tumors can be limited by uneven blood supply, stromal barriers, and incomplete tissue penetration.\n\nB-cell lymphomas provided an important clinical setting because they are radiation-sensitive and often express accessible surface antigens. Yttrium-90 ibritumomab tiuxetan targets CD20 and has been used in selected forms of non-Hodgkin lymphoma, including follicular lymphoma. Iodine-131 tositumomab was another CD20-directed product, historically important but later commercially discontinued. Commercial availability and clinical use have differed across countries and over time.\n\nRadiolabeled antibodies can irradiate antigen-bearing cells and neighboring cells that do not express the antigen, particularly with beta emitters. This cross-fire effect can be useful in heterogeneous disease. It also means that antigen specificity does not make radiation exposure exclusive to malignant cells. Marrow suppression is a central limitation, especially when lymphoma involves the marrow or when previous treatments have reduced hematopoietic reserve. Some regimens incorporate an unlabeled antibody as part of their established administration sequence.\n\nAnother systemic application uses iodine-131–labeled metaiodobenzylguanidine, or MIBG, an analogue of norepinephrine taken up by the norepinephrine transporter. MIBG can accumulate in neuroblastoma and in some pheochromocytomas and paragangliomas. Therapeutic use depends on demonstrable uptake and the particular disease setting. High administered activities may produce substantial marrow toxicity, and selected intensive protocols have used hematopoietic stem-cell support. MIBG-directed treatment is biologically distinct from somatostatin receptor therapy, even though some tumors can express targets relevant to both.\n\nHistorically, phosphorus-32 was used for certain myeloproliferative disorders because it could suppress proliferating hematopoietic tissue. Its use declined as alternative treatments became available and concern about delayed leukemogenic effects shaped practice. Contemporary investigational strategies include antibodies directed against hematologic antigens for conditioning before hematopoietic stem-cell transplantation, as well as pretargeting systems in which antibody localization and radionuclide administration occur in separate steps. These approaches seek to reduce circulating radioactivity while retaining tumor irradiation."
    },
    {
      "heading": "Locoregional treatment and radiation synovectomy",
      "text": "Locoregional radionuclide therapy places radioactivity in a defined organ, vascular territory, or body compartment. Its selectivity depends partly on anatomy and administration technique rather than solely on molecular recognition. The principal examples are hepatic radioembolization and radiation synovectomy. Although their physics overlaps with systemic therapy, their distribution, planning procedures, and complications are substantially different.\n\nRadioembolization, also called selective internal radiation therapy, delivers radioactive microspheres through the hepatic arterial circulation. Yttrium-90 microspheres are widely used; holmium-166 microspheres are another platform. The rationale is that many liver tumors receive a substantial share of their blood supply from hepatic arteries, whereas normal liver has a major portal venous contribution. Microspheres become lodged in small vessels and irradiate nearby tissue. Treatment has applications in hepatocellular carcinoma and selected liver metastases.\n\nPlanning involves arterial mapping and assessment of pathways that could carry particles outside the intended territory. A technetium-99m macroaggregated albumin study is commonly used before yttrium-90 treatment to estimate distribution and pulmonary shunting, although it does not perfectly reproduce microsphere behavior. Unintended delivery to the stomach or duodenum can cause serious ulceration, and excessive lung exposure can cause radiation injury. Functional liver reserve and the amount of healthy liver irradiated are major determinants of tolerability.\n\nDose calculation in radioembolization has increasingly distinguished tumor, normal liver, and lung compartments instead of treating the entire perfused volume as uniform. Highly selective administration to a small hepatic territory is sometimes termed radiation segmentectomy. The balance between local tumor control and liver toxicity differs among primary liver cancer, metastatic disease, and patients with underlying cirrhosis. Results from one disease or delivery technique are therefore not automatically applicable to another.\n\nRadiation synovectomy, also called radiosynoviorthesis, introduces a radiocolloid into a joint to treat persistent synovial inflammation. Uptake by the synovial lining produces local irradiation and subsequent reduction of inflamed synovial tissue. Radionuclides such as yttrium-90, rhenium-186, and erbium-169 have been used for different joint sizes because their particle ranges differ. Applications include selected inflammatory arthropathies and recurrent bleeding-related synovitis in hemophilia. Leakage outside the joint can injure surrounding tissues, making intra-articular placement and particle retention central to the procedure. Availability and accepted indications vary considerably among jurisdictions."
    },
    {
      "heading": "Clinical assessment, toxicity, and radiation protection",
      "text": "Clinical assessment connects the biological target to the patient’s overall condition. Relevant factors include disease extent, target expression, prior treatment, renal function, marrow reserve, liver function, and the likely distribution of radioactivity. A positive scan alone does not establish that a treatment will provide benefit. Rapidly progressive target-negative lesions, for example, may remain untreated even when other lesions show strong tracer uptake.\n\nBaseline and follow-up laboratory evaluation commonly includes a complete blood count and measures of kidney and liver function, selected according to the agent. Imaging characterizes both target expression and anatomical disease burden. Some treatments require assessment of hormone secretion, because irradiation of endocrine tumors can occasionally trigger acute hormonal effects. Multidisciplinary interpretation is important where radionuclide treatment intersects with surgery, external-beam radiotherapy, systemic anticancer drugs, and palliative care.\n\nToxicity depends on which normal tissues accumulate or are exposed to the agent. Marrow irradiation may produce anemia, thrombocytopenia, or neutropenia. Renal exposure is important for many radiolabeled peptides and small molecules; salivary effects are prominent with radioiodine and some PSMA-directed treatments. Liver toxicity is particularly relevant to hepatic radioembolization. Acute fatigue, nausea, and transient discomfort can occur, while organ dysfunction and second malignancies may emerge only after longer follow-up.\n\nRadiation protection addresses both external radiation and radioactive contamination. External exposure depends on emitted radiation, retained activity, distance, and time. Contamination can occur through urine, vomit, blood, or other bodily fluids, depending on the agent’s excretion. The radiation-protection team assesses these pathways and establishes facility procedures, waste handling, and release criteria under applicable regulations. Whether administration is inpatient or outpatient depends on the radionuclide, activity, measured or calculated exposure, and national rules.\n\nPregnancy and breastfeeding require particular attention because radionuclides can cross the placenta or enter breast milk, and some concentrate in fetal or infant tissues. Separate considerations apply to fertility and gonadal exposure. Treatment-related travel documentation may also be relevant because residual radioactivity can activate sensitive radiation detectors. These operational issues are part of patient safety, not evidence that ordinary social contact inevitably creates a major hazard; actual exposure depends on the specific treatment and circumstances."
    },
    {
      "heading": "Historical development, production, and service infrastructure",
      "text": "The origins of radionuclide therapy lie in the discovery of radioactivity and the early medical use of radium. The development of cyclotrons and nuclear reactors made it possible to produce radionuclides in quantities suitable for clinical investigation. A landmark occurred in 1941, when Saul Hertz and Arthur Roberts treated a patient with hyperthyroidism using radioiodine in Boston. Radioiodine subsequently became one of the earliest successful examples of treatment exploiting a tissue’s distinctive biochemical function.\n\nThe expansion from simple ions to targeted molecules required advances in radiochemistry, receptor biology, antibody technology, and imaging. Radioiodinated compounds and bone-seeking agents were followed by radiolabeled antibodies and receptor-binding peptides. Clinical development of somatostatin receptor therapy during the 1990s and later randomized trials helped establish modern targeted radiopharmaceutical treatment. PSMA-directed agents extended the theranostic model to a common solid tumor.\n\nProduction methods differ by radionuclide. Nuclear reactors can generate therapeutic isotopes through neutron irradiation; accelerators produce others through charged-particle reactions. Some radionuclides are obtained from generators containing a longer-lived parent. Lutetium-177 can be produced through direct neutron irradiation of lutetium-176 or through an indirect ytterbium-176 route. These routes differ in specific activity, purification requirements, and radionuclidic impurity profiles. The production route can therefore affect manufacturing and waste management as well as supply.\n\nA therapeutic preparation requires more than the presence of the correct isotope. Quality control assesses identity, activity, radiochemical purity, relevant radionuclidic and chemical impurities, and microbiological quality appropriate to the product. Chelator loading, reaction temperature, acidity, and radiolysis can influence labeling performance. Because radioactive decay continues throughout production, testing, transport, and administration, manufacturing schedules are closely linked to clinical schedules. Short interruptions can make a batch unusable or reduce the activity available at its intended administration time.\n\nClinical delivery requires coordinated radiopharmacy, nuclear medicine, medical physics, nursing, oncology, and, for catheter-based procedures, interventional radiology. Facilities need activity measurement, contamination monitoring, suitable shielding, emergency procedures, and waste-storage arrangements. Access also depends on isotope supply, trained personnel, reimbursement, and transport networks. These requirements help explain why a treatment supported by clinical evidence may nevertheless have limited availability in some health systems."
    },
    {
      "heading": "Evidence, individualization, and unresolved questions",
      "text": "Radionuclide therapy encompasses treatments with very different evidence bases. Radioiodine has decades of observational and clinical experience; newer radioligand therapies increasingly have large phase 3 trials. Evidence cannot be transferred simply because two products share a radionuclide or target. A change in ligand, chelator, particle, administration route, or decay chain can alter biodistribution, absorbed dose, and toxicity. Likewise, imaging response, biochemical response, symptom relief, and survival are distinct clinical endpoints.\n\nOne unresolved issue is how extensively treatment should be individualized using absorbed-dose measurements. Many established regimens use fixed activities or predefined activity schedules, sometimes adjusted for toxicity. Patient-specific dosimetry can identify substantial variation in tumor and organ exposure, but its routine implementation requires serial measurements, validated software, staff time, and evidence that changing activity improves outcomes. Organ-dose limits derived from external-beam radiotherapy cannot always be transferred directly because dose rate, fractionation, and microscopic distribution differ.\n\nTumor heterogeneity is another major limitation. Different lesions in the same patient may express different amounts of a target, and expression can change under treatment pressure. A tumor can progress through loss of the targeted receptor, altered cellular uptake, increased repair capacity, or expansion of previously minor resistant populations. Imaging can reveal some of this heterogeneity, but limited spatial resolution and tracer-specific behavior leave uncertainty at the cellular level.\n\nTargeted alpha therapy is being investigated to exploit high-energy deposition over short distances. Its potential advantages must be weighed against target-organ toxicity, heterogeneous delivery, daughter redistribution, and constrained isotope supply. Salivary toxicity has been an important limitation in some actinium-225 PSMA studies. Comparative trials are needed to establish where alpha-emitting agents provide benefits beyond established beta-emitting treatments rather than merely producing different imaging or biochemical responses.\n\nOther active questions concern combinations with chemotherapy, DNA-repair inhibitors, immunotherapy, and external-beam radiation; treatment sequencing; re-treatment after an earlier response; and use in lower-volume or earlier-stage disease. Combination treatment may increase tumor injury but can also compound marrow or organ toxicity. Trials therefore assess not only tumor control but also survival, late adverse effects, and health-related quality of life. Long follow-up is especially important when treatment moves into populations expected to live for many years."
    }
  ],
  "links": [
    "nuclear-medicine",
    "cancer",
    "radiation-therapy",
    "brachytherapy",
    "isotope",
    "electron",
    "alpha-particle",
    "dna",
    "pharmacokinetics",
    "chelation",
    "positron-emission-tomography",
    "single-photon-emission-computed-tomography",
    "hormone",
    "hyperthyroidism",
    "graves-disease",
    "hypothyroidism",
    "surgery",
    "pregnancy",
    "pancreas",
    "somatostatin",
    "randomized-controlled-trial",
    "bone-marrow",
    "nausea",
    "myelodysplastic-syndrome",
    "acute-myeloid-leukemia",
    "prostate-cancer",
    "antibody",
    "non-hodgkin-lymphoma",
    "follicular-lymphoma",
    "hematopoietic-stem-cell-transplantation",
    "liver-cancer",
    "cirrhosis",
    "complete-blood-count",
    "palliative-care",
    "anemia",
    "neutropenia",
    "patient-safety",
    "interventional-radiology",
    "health-system",
    "clinical-endpoint",
    "chemotherapy",
    "cancer-immunotherapy",
    "health-related-quality-of-life"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}